RT Journal Article
SR Electronic
T1 Elevated Serum β-Defensins Concentrations in Patients with Lung Cancer
JF Anticancer Research
JO Anticancer Res
FD International Institute of Anticancer Research
SP 4051
OP 4058
VO 24
IS 6
A1 YASUJI ARIMURA
A1 JUN-ICHI ASHITANI
A1 SHIGEHISA YANAGI
A1 MASATOSHI TOKOJIMA
A1 KOH ABE
A1 HIROSHI MUKAE
A1 MASAMITSU NAKAZATO
YR 2004
UL http://ar.iiarjournals.org/content/24/6/4051.abstract
AB Background: Beta-defensins (HBDs) are expressed in lung epithelial cells and act as antimicrobial agents. Most lung cancers that originate from pulmonary epithelial cells may produce HBDs. Materials and Methods: We measured serum HBD-1 and HBD-2 levels in healthy subjects (HS), patients with lung cancer and patients with pneumonia by radioimmunoassay. Results: Serum HBD-1 levels were higher in patients with lung cancer than HS and patients with pneumonia. Serum HBD-2 levels were higher in patients with lung cancer than HS. When cut-off values for positive HBD-1 were set at mean + 2SD of HS, the sensitivity and specificity of HBD-1 for the whole group of patients with lung cancer were 76.4 and 94.0 %, respectively, and the proportion of patients with HBD-1-positive lung cancer and clinical stage I was 69.2 %. Conclusion: Serum HBDs levels were high in patients with lung cancer and the serum HBD-1 level could be used as an auxiliary diagnostic tool for lung cancer. Copyright© 2004 International Institute of Anticancer Research (Dr. John G. Delinassios), All rights reserved